Restoration of miR-330 expression suppresses lung cancer cell viability, proliferation, and migration.
A549 Cells
Apoptosis
/ genetics
Biomarkers, Tumor
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Cell Survival
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
Genes, Tumor Suppressor
/ physiology
Humans
Lung Neoplasms
/ genetics
MicroRNAs
/ genetics
RNA, Messenger
/ genetics
apoptosis
cell cycle
lung cancer
miR-330
migration
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
29
02
2020
revised:
29
04
2020
accepted:
21
05
2020
pubmed:
26
6
2020
medline:
28
8
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
Lung cancer is one of the most common cancers and its incidence is rising around the world. Various studies suggest that miR-330 acts as a tumor-suppressor microRNA (miRNA) in different types of cancers, but precisely how has remained unclear. In this study, we investigate miR-330 expression in lung cancer patient samples, as well as in vitro, by studying how normalization of miR-330 expression affects lung cancer cellular phenotypes such as viability, apoptosis, proliferation, and migration. We establish that low miR-330 expression predicts poor lung cancer prognosis. Stable restoration of reduced miR-330 expression in lung cancer cells reduces cell viability, increases the fraction of apoptotic cells, causes G2/M cell cycle arrest, and inhibits cell migration. These findings are substantiated by increased mRNA and protein expression of markers for apoptosis via the intrinsic pathway, such as caspase 9, and decreased mRNA and protein expression of markers for cell migration, such as vimentin, C-X-C chemokine receptor type 4, and matrix metalloproteinase 9. We showed that reduced miR-330 expression predicts poor lung cancer survival and that stable restoration of miR-330 expression in lung cancer cells has a broad range of tumor-suppressive effects. This indicates that miR-330 is a promising candidate for miRNA replacement therapy for lung cancer patients.
Substances chimiques
Biomarkers, Tumor
0
MIRN330 microRNA, human
0
MicroRNAs
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
273-283Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Alla, V., Engelmann, D., Niemetz, A., Pahnke, J., Schmidt, A., Kunz, M., … Pützer, B. M. (2010). E2F1 in melanoma progression and metastasis. Journal of the National Cancer Institute, 102(2), 127-133.
Asghariazar, V., Sakhinia, E., Mansoori, B., Mohammadi, A., & Baradaran, B. (2019). Tumor suppressor microRNAs in lung cancer: An insight to signaling pathways and drug resistance. Journal of Cellular Biochemistry, 120(12), 19274-19289.
Boolell, V., Alamgeer, M., Watkins, D., & Ganju, V. (2015). The evolution of therapies in non-small cell lung cancer. Cancers, 7(3), 1815-1846.
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nature Medicine, 12(5), 585-591.
Caldas, C., & Brenton, J. D. (2005). Sizing up miRNAs as cancer genes. Nature Medicine, 11(7), 712-714.
Esmailzadeh, S., Mansoori, B., Mohammadi, A., Shanehbandi, D., & Baradaran, B. (2017). siRNA-mediated silencing of HMGA2 induces apoptosis and cell cycle arrest in human colorectal carcinoma. Journal of Gastrointestinal Cancer, 48(2), 156-163.
Gao, M., Yin, H., & Fei, Z.-W. (2013). Clinical application of microRNA in gastric cancer in Eastern Asian area. World Journal of Gastroenterology, 19(13), 2019.
Ghazanchaei, A., Mansoori, B., Mohammadi, A., Biglari, A., & Baradaran, B. (2019). Restoration of miR-152 expression suppresses cell proliferation, survival, and migration through inhibition of AKT-ERK pathway in colorectal cancer. Journal of Cellular Physiology, 234(1), 769-776.
Hosseinahli, N., Aghapour, M., Duijf, P. H., & Baradaran, B. (2018). Treating cancer with microRNA replacement therapy: A literature review. Journal of Cellular Physiology, 233(8), 5574-5588.
Hosseini, M., Naghan, P. A., Karimi, S., SeyedAlinaghi, S., Bahadori, M., Khodadad, K., … Masjedi, M. R. (2009). Environmental risk factors for lung cancer in Iran: A case-control study. International Journal of Epidemiology, 38(4), 989-996.
Hunt, K. K., Green, M. C., & Buchholz, T. A. (2012). Diseases of the breast. Sabiston textbook of surgery (19th ed.). St. Louis, MO: Elsevier Saunders.
Kim, B. K., Yoo, H. I., Choi, K., & Yoon, S. K. (2015). miR-330-5p inhibits proliferation and migration of keratinocytes by targeting Pdia3 expression. FEBS Journal, 282(24), 4692-4702.
Kim, J., Mori, T., Chen, S. L., Amersi, F. F., Martinez, S. R., Kuo, C., … Morton, D. L. (2006). Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Annals of Surgery, 244(1), 113-120.
Kumari, A., Iwasaki, T., Pyndiah, S., Cassimere, E., Palani, C., & Sakamuro, D. (2015). Regulation of E2F1-induced apoptosis by poly (ADP-ribosyl) ation. Cell Death and Differentiation, 22(2), 311-322.
Larsen, J. E., & Minna, J. D. (2011). Molecular biology of lung cancer: Clinical implications. Clinics in Chest Medicine, 32(4), 703-740.
Lee, K.-H., Chen, Y.-L., Yeh, S., Hsiao, M., Lin, J., Goan, Y., & Lu, P.-J. (2009). MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene, 28(38), 3360-3370.
Li, Y., Zhu, X., Xu, W., Wang, D., & Yan, J. (2013). miR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42. Biochemical and Biophysical Research Communications, 431(3), 560-565.
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., … Ferrando, A. A. (2005). microRNA expression profiles classify human cancers. Nature, 435(7043), 834-838.
Mansoori, B., Mohammadi, A., Naghizadeh, S., Gjerstorff, M., Shanehbandi, D., Shirjang, S., … Duijf, P. H. (2020). miR-330 suppresses EMT and induces apoptosis by downregulating HMGA2 in human colorectal cancer. Journal of Cellular Physiology, 235(2), 920-931.
Mansoori, B., Mohammadi, A., Shirjang, S., & Baradaran, B. (2015). micro-RNAs: The new potential biomarkers in cancer diagnosis, prognosis and cancer therapy. Cellular and Molecular Biology, 61(5), 1-10.
Mansoori, B., Mohammadi, A., Shirjang, S., & Baradaran, B. (2017). microRNAs in the diagnosis and treatment of cancer. Immunological Investigations, 46(8), 880-897.
Mao, Y., Chen, H., Lin, Y., Xu, X., Hu, Z., Zhu, Y., … Xie, L. (2013). microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells. Oncology Reports, 30(1), 327-333.
Meng, H., Wang, K., Chen, X., Guan, X., Hu, L., Xiong, G., … Bai, Y. (2015). microRNA-330-3p functions as an oncogene in human esophageal cancer by targeting programmed cell death 4. American Journal of Cancer Research, 5(3), 1062-1075.
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., … Restifo, N. P. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314(5796), 126-129.
Nature, C. G. A. R. N. J. (2012). Comprehensive genomic characterization of squamous cell lung cancers. Nature, 489(7417), 519-525.
Nikkola, J., Vihinen, P., Vuoristo, M.-S., Kellokumpu-Lehtinen, P., Kähäri, V.-M., & Pyrhönen, S. (2005). High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clinical Cancer Research, 11(14), 5158-5166.
Pierce, A. M., Schneider-Broussard, R., Gimenez-Conti, I. B., Russell, J. L., Conti, C. J., & Johnson, D. G. (1999). E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Molecular and Cellular Biology, 19(9), 6408-6414.
Qu, S., Yao, Y., Shang, C., Xue, Y., Ma, J., Li, Z., & Liu, Y. (2012). microRNA-330 is an oncogenic factor in glioblastoma cells by regulating SH3GL2 gene. PLOS One, 7(9), e46010.
Ruike, Y., Ichimura, A., Tsuchiya, S., Shimizu, K., Kunimoto, R., Okuno, Y., & Tsujimoto, G. (2008). Global correlation analysis for micro-RNA and mRNA expression profiles in human cell lines. Journal of Human Genetics, 53(6), 515-523.
Sassen, S., Miska, E. A., & Caldas, C. (2008). MicroRNA-Implications for cancer. Virchows Archiv, 452(1), 1-10.
Sehati, N., Sadeghie, N., Mansoori, B., Mohammadi, A., Shanehbandi, D., & Baradaran, B. (2020). MicroRNA-330 inhibits growth and migration of melanoma A375 cells: In vitro study. Journal of Cellular Biochemistry, 121(1), 458-467.
Shirjang, S., Mansoori, B., Mohammadi, A., Shajari, N., Duijf, P. H., Najafi, S., … Baradaran, B. (2020). miR-330 regulates colorectal cancer oncogenesis by targeting BACH1. Journal of Cell Physiology, 235(2), 920-931.
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64(1), 9-29.
Thangavelu, P. U., Krenács, T., Dray, E., & Duijf, P. H. (2016). In epithelial cancers, aberrant COL17A1 promoter methylation predicts its misexpression and increased invasion. Clinical Epigenetics, 8(120), 1-13.
Thangavelu, P. U., Lin, C.-Y., Vaidyanathan, S., Nguyen, T. H., Dray, E., & Duijf, P. H. (2017). Overexpression of the E2F target gene CENPI promotes chromosome instability and predicts poor prognosis in estrogen receptor-positive breast cancer. Oncotarget, 8(37), 62167-62182.
Vaidyanathan, S., Cato, K., Tang, L., Pavey, S., Haass, N. K., Gabrielli, B. G., & Duijf, P. H. (2016). In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis. Oncogene, 35(41), 5446-5455.
Vaidyanathan, S., Thangavelu, P. U., & Duijf, P. H. (2016). Overexpression of Ran GTPase components regulating nuclear export, but not mitotic spindle assembly, marks chromosome instability and poor prognosis in breast cancer. Targeted Oncology, 11(5), 677-686.
Wang, G., Gu, J., & Gao, Y. (2016). microRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer. Tumor Biology, 37(10), 13983-13993.
Yang, I. A., Holloway, J. W., & Fong, K. M. (2013). Genetic susceptibility to lung cancer and co-morbidities. Journal of Thoracic Disease, 5(Suppl. 5), S454.
Ye, Z., Zhang, X., Luo, Y., Li, S., Huang, L., Li, Z., … Chen, G. (2016). Prognostic values of vimentin expression and its clinicopathological significance in non-small cell lung cancer: A meta-analysis of observational studies with 4118 cases. PLOS One, 11(9), e0163162.
You, L., Shou, J., Deng, D., Jiang, L., Jing, Z., Yao, J., … Pan, Q. (2015). Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. Oncotarget, 6(37), 40268-40282.